A. Chase

发表

JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms

Andrew Collins, Andrew Chase, Nicholas C P Cross, 2009, Nature Genetics.

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

H. Drexler, D. Oscier, A. Jones, 2010, Nature Genetics.

Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia

W. Tapper, M. Hallek, W. Hofmann, 2017, Leukemia.

Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation.

J. Goldman, A. Chase, N. Cross, 1993 .

FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells

P. Marynen, C. Mecucci, M. Martelli, 2007, Leukemia.

Bone marrow transplantation for chronic myeloid leukaemia: the effects of differing criteria for defining chronic phase on probabilities of survival and relapse

A. Chase, J. Apperley, Richard Szydlo, 1997, British journal of haematology.

Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome.

A. Chase, F. Grand, N. Cross, 2007, Blood.

Non‐random involvement of chromosome 13 in patients with persistent or relapsed disease after bone‐marrow transplantation for chronic myeloid leukemia

J. Goldman, A. Chase, N. Cross, 2000, Genes, chromosomes & cancer.

Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome.

A. Chase, F. Grand, N. Cross, 2007, Blood.

Cytogenetic and Molecular Monitoring of Residual Disease in Chronic Myeloid Leukaemia

J. Goldman, A. Chase, J. Kaeda, 2002, Acta Haematologica.

PRR14L mutations are associated with chromosome 22 acquired uniparental disomy, age related clonal hematopoiesis and myeloid neoplasia

W. Tapper, J. Dumanski, A. Chase, 2018, Leukemia.

imatinib or interferon alpha Minimal molecular response in polycythemia vera patients treated with

D. Oscier, A. Jones, A. Chase, 2011 .

Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha.

D. Oscier, A. Jones, A. Chase, 2005, Blood.

Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms

Paola Guglielmelli, Torsten Haferlach, William Tapper, 2015, Nature Communications.

Constitutional genetic association with CALR mutations?

J. Vizmanos, A. Chase, N. Cross, 2015, Leukemia.

chronic myeloid leukemia Factors affecting duration of survival after onset of blastic transformation of

D. Marin, J. Goldman, A. Chase, 2013 .

ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response.

I. Lampert, J. Goldman, A. Chase, 2002, American journal of clinical pathology.

Detection of leukemia-associated mutations in peripheral blood DNA of hematologically normal elderly individuals

J. Dumanski, A. Jones, A. Chase, 2015, Leukemia.

Identification of four new translocations involving FGFR1 in myeloid disorders

G. Martinelli, D. Oscier, M. Corcoran, 2001, Genes, chromosomes & cancer.

Recurrent activating STAT 5 B N 642 H mutation in myeloid neoplasms 1 with eosinophilia

B. Bain, W. Tapper, J. Cavenagh, 2018 .

Fusion of H4/D10S170 to the platelet-derived growth factor receptor beta in BCR-ABL-negative myeloproliferative disorders with a t(5;10)(q33;q21).

S. Kulkarni, J. Goldman, A. Chase, 2000, Cancer research.

Frequent Inactivating Mutations of TET2 and CBL Are Associated with Acquired Uniparental Disomy in Atypical Chronic Myeloid Leukemia and Related Disorders.

W. Vainchenker, A. Chase, K. Zoi, 2009 .

BCR/ABL-negative progenitors are enriched in the adherent fraction of CD34+ cells circulating in the blood of chronic phase chronic myeloid leukemia patients

A. Chase, A. Reiter, M. Gordon, 1997, Leukemia.

Collection of Ph-negative progenitor cells from interferon responsive patients with chronic myeloid leukemia: effect of granulocyte-colony-stimulating factor mobilization.

C. Craddock, J. Goldman, A. Chase, 2000, Haematologica.

Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia

C. Craddock, J. Goldman, A. Chase, 2000 .

No evidence for microsatellite instability or consistent loss of heterozygosity at selected loci in chronic myeloid leukaemia blast crisis.

K. Mills, A. Chase, N. Cross, 1994, Leukemia.

Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse.

J. Goldman, A. Chase, N. Cross, 1994, Blood.

Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia

B. Bain, W. Tapper, J. Cavenagh, 2018, Leukemia.

Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation.

A. Chase, N. Cross, T. Hughes, 1993, Blood.

Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements

W. Hofmann, C. Haferlach, A. Chase, 2013, Haematologica.

Identification of PML/RARα rearrangements in suspected acute promyelocytic leukemia using fluorescence in situ hybridization of bone marrow smears: a comparison with cytogenetics and RT-PCR in MRC ATRA trial patients

A. Chase, D. Grimwade, A. Goldstone, 2000, Leukemia.

Inactivation of the retinoblastoma susceptibility gene in a human high grade non‐Hodgkin's lymphoma cell line

A. Chase, J. M. Goldman, J. Goldman, 1991, British journal of haematology.

A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy.

N. Russell, A. Chase, F. Grand, 2007, Experimental hematology.

Evolutional change of karyotype with t(8;9)(p22;p24) and HLA-DR immunophenotype in relapsed acute myeloid leukemia

A. Chase, A. Reiter, N. Cross, 2008, International journal of hematology.

The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1

C. Schoch, A. Chase, N. Cross, 2005, Leukemia.

P2X7 polymorphism and chronic lymphocytic leukaemia: lack of correlation with incidence, survival and abnormalities of chromosome 12

D. Oscier, L. Zhang, A. Chase, 2003, Leukemia.

Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation.

J. Goldman, A. Chase, N. Cross, 1996, Blood.

A high-throughput candidate gene mutation screen in lymphoproliferative and myeloproliferative neoplasias.

A. Chase, N. Cross, A. Hochhaus, 2009, Leukemia research.

Cloning and characterization of RNF6, a novel RING finger gene mapping to 13q12.

A. Chase, J. Sohal, N. Cross, 1999, Genomics.

Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/CSF1R signaling abnormalities in the cell line GDM1

J. Melo, L. Zhang, A. Jones, 2009, Leukemia.

Cytogenetics of chronic myeloid leukaemia.

A. Chase, N. Cross, B. Huntly, 2001, Best practice & research. Clinical haematology.

Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms.

K. Döhner, A. Jones, A. Chase, 2012, Blood.

Cytogenetic status pre-transplant as a predictor of outcome post bone marrow transplantation for chronic myelogenous leukaemia

A. Chase, J. Goldman, R. Szydlo, 2000, Bone Marrow Transplantation.

Abnormalities of chromosome band 8p11 in leukemia: two clinical syndromes can be distinguished on the basis of MOZ involvement.

R. Aguiar, A. Chase, A. Reiter, 1997, Blood.

Fusion of PDGFRB to two distinct loci at 3p21 and a third at 12q13 in imatinib‐responsive myeloproliferative neoplasms

A. Chase, F. Grand, N. Cross, 2010, British journal of haematology.

Correlation between the proportion of Philadelphia chromosome‐positive metaphase cells and levels of BCR‐ABL mRNA in chronic myeloid leukaemia

J. Goldman, A. Chase, N. Cross, 1995, Genes, chromosomes & cancer.

The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms.

P. Campbell, H. Grallert, A. Green, 2010, Blood.

TFG, a target of chromosome translocations in lymphoma and soft tissue tumors, fuses to GPR128 in healthy individuals

Andrew Collins, Philipp Erben, Stefan Schreiber, 2010, Haematologica.

The t(1;9)(p34;q34) and t(8;12)(p11;q15) fuse pre‐mRNA processing proteins SFPQ (PSF) and CPSF6 to ABL and FGFR1

D. Oscier, A. Chase, F. Grand, 2008, Genes, chromosomes & cancer.

Recurrent SETBP1 mutations in atypical chronic myeloid leukemia

Roberta Spinelli, Rocco Piazza, Torsten Haferlach, 2012, Nature Genetics.

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.

B. Bain, J. Melo, D. Marin, 2002, The New England journal of medicine.

Fusion of ETV6 to the caudal-related homeobox gene CDX2 in acute myeloid leukemia with the t(12;13)(p13;q12).

J. Goldman, A. Chase, A. Reiter, 1999, Blood.

Fusion of ETV 6 to the Caudal-Related Homeobox Gene CDX 2 in Acute Myeloid Leukemia

J. Goldman, A. Chase, A. Reiter, 1999 .

Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases.

A. Chase, N. Cross, 2006, Clinical science.

Characterization of a t(10;12)(q24;p13) in a case of CML in transformation

R. Aguiar, D. Oscier, J. Goldman, 1997, Genes, chromosomes & cancer.

Aberrations of EZH2 in Cancer

A. Chase, N. Cross, 2011, Clinical Cancer Research.

p53 in chronic myeloid leukemia cell lines.

S. Bi, J. Goldman, A. Chase, 1992, Leukemia.

Genome-wide association study identifies novel susceptibility loci for KIT D816V positive mastocytosis.

Toshiko Tanaka, S. Bandinelli, C. Gieger, 2021, American journal of human genetics.

A two‐color BCR–ABL probe that greatly reduces the false positive and false negative rates for fluorescence in situ hybridization in chronic myeloid leukemia

A. Chase, D. Nguyen, M. Gordon, 1998, Genes, chromosomes & cancer.

Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndrome.

R. Aguiar, S. Kulkarni, J. Goldman, 1998, Blood.

Consistent Fusion of ZNF 198 to the Fibroblast Growth Factor Receptor-1 in the t ( 8 ; 13 ) ( p 11 ; q 12 ) Myeloproliferative Syndrome

R. Aguiar, S. Kulkarni, Jesús M. Hernández, 1998 .

Lack of reciprocal translocation in BCR-ABL positive Ph-negative chronic myeloid leukaemia.

A. Chase, B. Garicochea, J. Goldman, 1994, Leukemia.

EZH2 in Myeloid Malignancies

A. Chase, N. Cross, A. Hochhaus, 2020, Cells.

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.

D. Oscier, A. Jones, A. Chase, 2005, Blood.

The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2.

H. F. Barker, C. Schoch, A. Chase, 2005, Cancer research.

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.

D. Oscier, A. Jones, A. Chase, 2005, Blood.

Is a Recurrent Abnormality in Chronic and Acute Leukemia that Fuses PCM 1 to JAK 2

H. F. Barker, C. Schoch, A. Chase, 2005 .

Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia.

D. Marin, J. Goldman, A. Chase, 2002, Blood.

Absence of host-derived cells in the blood of patients in remission after allografting for chronic myeloid leukemia.

J. Goldman, A. Chase, N. Cross, 2000, Blood.

Profound parental bias associated with chromosome 14 acquired uniparental disomy indicates targeting of an imprinted locus

H E White, W. Tapper, J. Dumanski, 2015, Leukemia.

Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors

J. Goldman, A. Chase, F. Dazzi, 1998, Bone Marrow Transplantation.

Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms.

A. Hall, D. Oscier, A. Jones, 2008, Blood.

Factors influencing the false positive and negative rates of BCR‐ABL fluorescence in situ hybridization

J. Goldman, A. Chase, F. Grand, 1997, Genes, chromosomes & cancer.

Phenotypic characterization of normal and CML CD34-positive cells: only the most primitive CML progenitors include Ph-neg cells.

A. Chase, J. Goldman, P. de Fabritiis, 1993, Leukemia & lymphoma.

Mutational mechanisms of EZH2 inactivation in myeloid neoplasms

A. Chase, N. Cross, A. Villasante, 2020, Leukemia.

Identification of a novel gene, FGFR1OP2, fused to FGFR1 in 8p11 myeloproliferative syndrome

D. Oscier, M. Corcoran, A. Chase, 2004, Genes, chromosomes & cancer.

Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074

A. Chase, N. Cross, A. Rahemtulla, 2004, Leukemia.

Pathogenic variants causing ABL1 malformation syndrome cluster in a myristoyl-binding pocket and increase tyrosine kinase activity

S. Robertson, D. Baralle, R. Heller, 2020, European Journal of Human Genetics.

Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome

Andrew Chase, Nicholas C P Cross, A. Chase, 2013, Haematologica.

Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia.

C. Craddock, J. Goldman, A. Chase, 2000, Blood.

Reconstitution with Philadelphia chromosome-negative recipient haematopoiesis early after allogeneic BMT for CML.

A. Chase, N. Cross, S. Rule, 1996, Bone marrow transplantation.

Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.

J. Melo, G. McArthur, J. Goldman, 2007, Blood.

p53-Binding Protein 1 Is Fused to the Platelet-Derived Growth Factor Receptor β in a Patient with a t(5;15)(q33;q22) and an Imatinib-Responsive Eosinophilic Myeloproliferative Disorder

G. Webersinke, E. Baxter, A. Chase, 2004, Cancer Research.

Frequent deletion of hSNF5/INI1, a component of the SWI/SNF complex, in chronic myeloid leukemia.

S. Kulkarni, J. Goldman, A. Chase, 1999, Cancer research.

A case of myelofibrosis with a t(4;13)(q25;q12): evidence for involvement of a second 13q12 locus in chronic myeloproliferative disorders

J. Goldman, A. Chase, N. Cross, 1999, British journal of haematology.

Origin and function of adherent lymphokine activated killer cells in patients with chronic myeloid leukaemia who relapse following bone marrow transplantation

S. Mackinnon, J. Goldman, A. Chase, 1991, British journal of haematology.

A polymorphism associated with STAT3 expression and response of chronic myeloid leukemia to interferon α

A. Chase, A. Reiter, N. Cross, 2010, Haematologica.

marrow transplantation BCR-ABL transcripts in chronic myeloid leukemia patients after bone Competitive polymerase chain reaction to estimate the number of

A. Chase, N. Cross, T. Hughes, 2011 .

Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia

B. Bain, W. Tapper, J. Cavenagh, 2018, Leukemia.

Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms

A. Jones, A. Chase, K. Zoi, 2010, Haematologica.

Assignment of the steroid receptor coactivator-1 (SRC-1) gene to human chromosome band 2p23.

R. Aguiar, A. Chase, N. Cross, 1998, Genomics.

Two cases of inv(8)(p11q13) in AML with erythrophagocytosis: a new cytogenetic variant

J. Goldman, A. Chase, D. Swirsky, 1998, British journal of haematology.

BCR‐ABL‐positive lymphoblastoid cells display limited proliferative capacity under in vitro culture conditions

J. Melo, J. Goldman, A. Chase, 1996, British journal of haematology.

T lymphocytes in chronic myelogenous leukaemia (CML): no evidence of the BCR/ABL fusion gene detected by fluorescence in situ hybridization in 14 patients.

A. Chase, B. Garicochea, J. Goldman, 1994, Leukemia.

Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes

W. Tapper, W. Hofmann, C. Haferlach, 2015, Annals of Hematology.

Identification of B56α, B56γ and BAP1 as PRR14L binding partners

A. Chase, N. Cross, J. Score, 2023, bioRxiv.

Aplasia after donor lymphocyte infusion (DLI) for CML in relapse after sex‐mismatched BMT: recovery of donor‐type haemopoiesis predicted by non‐isotopic in situ hybridization (ISH)

J. Goldman, A. Chase, N. Cross, 1994, British journal of haematology.

Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms.

Helen E White, Daniel Ward, Matthew Lyon, 2015, Leukemia research.

Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia.

C. Haferlach, A. Chase, A. Reiter, 2007, Blood.

Title 1 Pathogenic variants causing ABL 1 malformation syndrome cluster in a myristoyl-2 binding pocket and increase tyrosine kinase activity 3 4 Running title 5 ABL 1 pathogenic variants 6

S. Robertson, D. Baralle, R. Heller, 2020 .

Broad molecular screening of an unclassifiable myeloproliferative disorder reveals an unexpected ETV6/ABL1 fusion transcript

A. Gratwohl, A. Tichelli, A. Chase, 2005, Leukemia.

Widespread occurrence of the JAK 2 V 617 F mutation in chronic myeloproliferative disorders

D. Oscier, A. Jones, A. Chase, 2005 .

The JAK2 46/1 Haplotype Predisposes to Myeloproliferative Neoplasms Characterized by Diverse Mutations

P. Campbell, A. Green, S. Schnittger, 2009 .

Molecular characterization of EZH2 mutant patients with myelodysplastic/myeloproliferative neoplasms

C. Haferlach, A. Chase, N. Cross, 2017, Leukemia.

Assignment1 of ZNF262 to human chromosome band 1p34→p32 by in situ hybridization

A. Chase, J. Sohal, J. Goldman, 1999, Cytogenetic and Genome Research.

Molecular analysis of transient cytogenetic relapse after allogeneic bone marrow transplantation for chronic myeloid leukaemia.

J. Goldman, A. Chase, F. van Rhee, 1996, Bone Marrow Transplantation.

Testing in-vitro for imatinib sensitivity in BCR-ABL negative myeloproliferative disorders

A. Chase, N. Cross, K. Higley, 2003 .

Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms.

K. Döhner, A. Jones, A. Chase, 2012, Blood.

No evidence for persistence of BCR-ABL-positive cells in patients in molecular remission after conventional allogenic transplantation for chronic myeloid leukemia.

D. Niederwieser, A. Chase, R. Krahl, 2000, Blood.

No evidence for persistence of BCR-ABL-positive cells in patients in molecular remission after conventional allogeneic transplantation for chronic myeloid leukemia

J. Goldman, A. Chase, N. Cross, 2000 .

The t(1;9)(p34;q34) and t(8;12)(p11;q15) fuse pre‐mRNA processing proteins SFPQ (PSF) and CPSF6 to ABL and FGFR1

D. Oscier, A. Chase, F. Grand, 2008, Genes, chromosomes & cancer.